Fig. 3
From: YWHAG promotes the progression of lung adenocarcinoma through the JAK2/STAT3 pathway
YWHAG predicted treatment efficacy. (A-D) The estimated IC50 of Cisplatin, Docetaxel, Paclitaxel and Erlotinib between two groups in GSE31210 cohort. (E-H) The estimated IC50 of Cisplatin, Docetaxel, Paclitaxel and Erlotinib between two groups in GSE41271 cohort. (I-L) The estimated IC50 of Cisplatin, Docetaxel, Paclitaxel and Erlotinib between two groups in GSE50081 cohort